Suppliers and packagers for generic pharmaceutical drug: BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch And Lomb	NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC	bacitracin zinc; neomycin sulfate; polymyxin b sulfate	OINTMENT;OPHTHALMIC	064064	ANDA	Bausch & Lomb Incorporated	24208-780-55	1 TUBE in 1 CARTON (24208-780-55) / 3.5 g in 1 TUBE	1995-10-30

Suppliers and packagers for generic pharmaceutical drug: BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

Last updated: April 24, 2026

Who Supplies Bacitracin Zinc, Neomycin Sulfate, and Polymyxin B Sulfate?

Do these actives have a stable supplier ecosystem?

Yes. Each of bacitracin zinc, neomycin sulfate, and polymyxin B sulfate is widely sourced for pharmaceutical and pharmaceutical-derivative use, with manufacturing concentrated among established API and specialty antimicrobial ingredient suppliers. Supplier availability is typically anchored by:

• Regulatory and quality infrastructure (DMF/CEP support, GMP compliance, microbiology traceability).
• Form factor fit (API powders, standardized lots, particle size specs where required).
• Downstream pathway (ophthalmic, otic, topical, and inhaled where applicable).

What is the supplier landscape for bacitracin zinc?

Bacitracin zinc is commonly supplied by global antimicrobial and antibiotic specialty ingredient companies and several general-purpose API manufacturers with fermentation/antimicrobial capabilities.

Commonly used supplier types

• Specialty antibiotic ingredient manufacturers (bacitracin-focused or broad antimicrobial portfolios)
• API distributors with long-standing manufacturer coverage (provide ready-to-form packaging and documentation)

Typical documentation supplied by qualified suppliers

• GMP manufacturing evidence (often site-specific)
• CoA with identity/potency specs
• Stability and impurity profiles where the customer qualification requires them
• Regulatory file linkage (DMF or equivalent, depending on market)

What is the supplier landscape for neomycin sulfate?

Neomycin sulfate is a mature aminoglycoside ingredient with broad sourcing across fermentation-derived antibiotic supply chains.

Commonly used supplier types

• Aminoglycoside fermentation suppliers
• General antibiotic API suppliers that support aseptic and topical grade needs

Common qualification points

• Potency consistency (units-based specs are common)
• Impurity controls (aminoglycoside impurity profiles)
• Microbiological and particle-size alignment with finished product requirements

What is the supplier landscape for polymyxin B sulfate?

Polymyxin B sulfate is sourced through established antibiotic producers due to narrow-spec microbiological potency requirements and supply variability.

Commonly used supplier types

• Polymyxin-focused antimicrobial producers
• Antibiotic API manufacturers with strong fermentation QA/QC systems

Common qualification points

• Potency and content uniformity (lot-to-lot)
• Sulfate form verification and identity methods
• Impurity and degradation monitoring

---

Which suppliers are typically used for these three actives?

Bacitracin zinc suppliers

The supplier set for bacitracin zinc is dominated by fermentation and antibiotic ingredient specialists and their qualified manufacturing sites. Typical names used in procurement workflows include major antibiotic ingredient producers and long-running API ingredient suppliers (often paired with distributor coverage).

Neomycin sulfate suppliers

Neomycin sulfate is supplied by a larger set of antibiotic fermentation and API ingredient companies due to mature production footprint and downstream demand across topical and otic products.

Polymyxin B sulfate suppliers

Polymyxin B sulfate is supplied by fewer fermentation specialists relative to neomycin sulfate, with supplier decisions often driven by potency stability, regulatory support, and lead-time reliability.

---

Supplier short-listing criteria that determine which companies get picked

For procurement and R&D, the gating requirements usually narrow the supplier field quickly:

1. Regulatory file support

   • DMF/CEP availability
   • Ability to align with target jurisdictions (US, EU, UK, etc.)

2. GMP readiness

   • GMP certificate and audit history
   • Controlled packaging and labeled chain-of-custody

3. Quality spec match

   • Potency and identity methods
   • Impurity profile acceptance criteria

4. Supply reliability

   • Lead times with historical performance
   • Multi-site capability or dual-source availability

5. Commercial terms

   • MOQ, packaging size options
   • Pricing stability and change-notification terms

---

What finished-product users typically require from suppliers

When these actives are used in finished drug products (commonly topical, ophthalmic, or otic formulations), suppliers normally must provide:

• API CoA for each lot with potency and identity results
• Analytical methods (or method descriptions) adequate for customer verification
• Change control mechanisms for spec changes, sourcing changes, and analytical method updates
• Stability data appropriate to shelf-life targets or a compatibility package for qualification

---

Key Takeaways

• All three actives have established global supplier ecosystems, with neomycin sulfate generally showing the broadest supplier pool and polymyxin B sulfate the most constrained.
• Supplier selection hinges on regulatory file support, GMP readiness, potency/impurity control, and supply reliability, not just price or availability.
• A defensible short list is built by matching jurisdictional documentation (DMF/CEP), lot release specs, and change-control maturity to the downstream finished product requirements.

---

FAQs

1) Are these APIs typically sourced as finished API powders or standardized mixtures?

They are typically sourced as API powders in the required salt form (bacitracin zinc, neomycin sulfate, polymyxin B sulfate) with lot-by-lot potency and identity documentation.

2) What spec drivers most often disqualify a supplier?

Failures usually come from potency drift, impurity nonconformance, identity method mismatch, or inadequate regulatory documentation linkage.

3) Which of the three is most sensitive to lot-to-lot variation?

Polymyxin B sulfate often shows tighter practical sensitivity due to potency and impurity controls required for consistent downstream performance.

4) Do suppliers commonly support DMF-style regulatory submissions?

Many do, but it depends on the site and geography. Procurement workflows typically confirm whether a supplier can support jurisdiction-specific regulatory file requirements.

5) How do lead times usually behave for these antibiotics?

Lead times vary by fermentation cycle and market demand. Neomycin sulfate tends to show better sourcing flexibility than polymyxin B sulfate.

---

References

[1] European Directorate for the Quality of Medicines and HealthCare (EDQM). CEP information and quality documents. https://www.edqm.eu
[2] U.S. Food and Drug Administration (FDA). Drug Master Files (DMF). https://www.fda.gov/drugs/drug-master-files-dmfs
[3] U.S. FDA. Current Good Manufacturing Practice (CGMP) regulations for APIs and finished pharmaceuticals. https://www.fda.gov/drugs/pharmaceutical-quality-resources
[4] World Health Organization (WHO). Guidelines for the production and quality control of antibiotics and related substances. https://www.who.int/publications